×

US FDA approves Roche’s oral treatment for advanced breast cancer

By Thomson Reuters Nov 16, 2026 | 2:46 PM

Nov 16 (Reuters) – The US Food and Drug Administration approved Roche’s oral treatment ​for certain patients with ‌a type of advanced breast cancer, the regulator said on Monday.

The drug, giredestrant, was approved in ‌combination ​with everolimus for ⁠adults with estrogen ⁠receptor-positive, HER2-negative locally advanced or metastatic cancer, whose cancer carries an ESR1 mutation ​and has returned or worsened during or after hormone-based ⁠treatment.

The approval ⁠was based on a ​late-stage study in 207 patients ​with ESR1-mutated tumors, in which the ‌combination reduced the risk of disease progression or death by 62%.

The combination delayed ⁠cancer progression for a median of 10 months, compared with 5.5 months ⁠for ‌another hormone treatment ⁠given with everolimus.

The recommended ​dose ‌is 30 milligrams once ​daily, ⁠and the FDA also authorized a blood test to identify eligible patients.

(Reporting by Sahil Pandey in Bengaluru; Editing by ​Shinjini Ganguli)